SynthesisBMC cancer2021

Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.

Le-Tian Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.